Evotec is a drug manufacturers - specialty & generic business based in the US. Evotec shares (EVO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.76 – a decrease of 10.19% over the previous week. Evotec employs 5,007 staff and has a trailing 12-month revenue of around $777.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.76 |
|---|---|
| 52-week range | $2.85 - $12.00 |
| 50-day moving average | $3.55 |
| 200-day moving average | $5.15 |
| Wall St. target price | $6.20 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.52 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.49 from 2024-11-22
| 1 week (2024-11-20) | -15.28% |
|---|---|
| 1 month (2024-10-25) | 27.56% |
| 3 months (2024-08-27) | 18.16% |
| 6 months (2024-05-24) | -5.87% |
| 1 year (2023-11-27) | -54.46% |
|---|---|
| 2 years (2022-11-25) | -49.44% |
| 3 years (2021-11-26) | 23.73 |
| 5 years (2019-11-27) | 10.7 |
Valuing Evotec stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Evotec's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Evotec's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $15.9 million.
The EBITDA is a measure of a Evotec's overall financial performance and is widely used to measure a its profitability.
To put Evotec's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $777.1 million |
|---|---|
| Gross profit TTM | $151.5 million |
| Return on assets TTM | -1.77% |
| Return on equity TTM | -16.25% |
| Profit margin | -22.05% |
| Book value | $5.46 |
| Market Capitalization | $1.7 billion |
TTM: trailing 12 months
We're not expecting Evotec to pay a dividend over the next 12 months.
You may also wish to consider:
Evotec's shares were split on a 4:1 basis on 19 October 2021 . So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Evotec shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for Evotec shares which in turn could have impacted Evotec's share price.
Over the last 12 months, Evotec's shares have ranged in value from as little as $2.85 up to $11.9999. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evotec's is 0.984. This would suggest that Evotec's shares are less volatile than average (for this exchange).
To put Evotec's beta into context you can compare it against those of similar companies.
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc. ; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.